For many patients, the onset of cholangitis is sudden and frightening. It typically presents as a sharp pain in the upper right abdomen, accompanied by high fever and chills. This condition, which involves inflammation and infection of the bile duct system, is often a medical emergency that disrupts normal digestion and overall stability. The uncertainty of a hospital visit and the intensity of the symptoms can be overwhelming. However, with prompt medical intervention, the infection can be brought under control. 

Treatment is critical because the bile ducts play a vital role in carrying bile from the liver to the small intestine. When these ducts become blocked usually by a gallstone and infected, the bacteria can spread quickly to the liver or bloodstream, leading to sepsis. The primary goals of treatment are to clear the bacterial infection, relieve pain, and eventually address the blockage to prevent recurrence. Treatment plans are tailored based on whether the condition is an acute infection or a chronic issue, as well as the severity of the patient’s symptoms (Johns Hopkins Medicine, 2023). 

Overview of treatment options for Cholangitis 

The immediate treatment priority for acute cholangitis is stabilizing the patient and fighting the infection. This is almost always managed in a hospital setting. The approach relies heavily on powerful antibiotics to stop the bacterial spread. 

While medications are the first line of defense to control the infection, they are often a bridge to a procedure. Once the patient is stable and the antibiotics have reduced the inflammation, procedures like Endoscopic Retrograde Cholangiopancreatography (ERCP) are typically performed to physically remove the blockage (stones or sludge). For patients with chronic forms of the disease, such as Primary Biliary Cholangitis (PBC), the focus shifts to long-term oral medications that improve bile flow and protect the liver. 

Medications used for Cholangitis 

Antibiotics are the cornerstone of treating acute cholangitis. Because the infection is often caused by bacteria from the gut entering the bile ducts, doctors initiate “broad-spectrum” antibiotics immediately. 

Common first-line antibiotic regimens include cephalosporins (such as ceftriaxone) or penicillins combined with beta-lactamase inhibitors (like piperacillin-tazobactam). These are often paired with metronidazole to ensure comprehensive coverage against anaerobic bacteria. Clinical experience suggests that starting these medications intravenously as soon as possible significantly improves outcomes. 

For managing the intense pain associated with the biliary obstruction, doctors prescribe analgesics. Non-steroidal anti-inflammatory drugs (NSAIDs) may be used cautiously, but opioids are sometimes necessary for severe pain management in a controlled setting. 

In cases of chronic cholangitis (like PBC), a different class of medication is used. Ursodiol (ursodeoxycholic acid) is the standard treatment. This naturally occurring bile acid helps move bile through the liver and reduces liver damage. It is a long-term, daily medication rather than an acute fix (Mayo Clinic, 2022). 

How these medications work 

Antibiotics function by targeting the structural integrity of the bacteria causing the infection. Drugs like penicillins and cephalosporins attack the bacterial cell wall, causing the bacteria to rupture and die. Metronidazole works by disrupting the DNA inside the bacteria, preventing them from reproducing. By reducing the bacterial load, these drugs stop the infection from overwhelming the immune system. 

Ursodiol works by changing the composition of the bile. It replaces more toxic bile acids with a non-toxic form and helps thin the bile. This makes it easier for the fluid to flow through the ducts, reducing inflammation and preventing bile from backing up into the liver, which causes scarring over time. 

Side effects and safety considerations 

Strong antibiotics often cause digestive issues (nausea, vomiting, diarrhea) and can lead to secondary infections like severe C. difficile diarrhea. Ursodiol is usually well-tolerated, though some patients experience back pain, dizziness, or indigestion. 

Safety monitoring is crucial. Since cholangitis affects the liver, regular blood tests check liver enzyme levels to monitor medication effectiveness and organ stress. Patients must immediately seek medical help for a return of high fever, confusion, or jaundice (yellowing skin/eyes), as these signal persistent blockage or worsening infection (MedlinePlus, 2021). 

Since everyone’s experience with the condition and its treatments can vary, working closely with a qualified healthcare provider helps ensure safe and effective care. 

References 

  1. Johns Hopkins Medicine. https://www.hopkinsmedicine.org 
  1. Mayo Clinic. https://www.mayoclinic.org 
  1. MedlinePlus. https://medlineplus.gov 
  1. National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov 

Medications for Cholangitis

These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Cholangitis.

Found 4 Approved Drugs for Cholangitis

Ursodiol

Brand Names
Urso 250, Reltone, Urso

Ursodiol

Brand Names
Urso 250, Reltone, Urso
Ursodiol capsules are indicated for patients with radiolucent, noncalcified gallbladder stones <20 mm in greatest diameter in whom elective cholecystectomy would be undertaken except for the presence of increased surgical risk due to systemic disease, advanced age, idiosyncratic reaction to general anesthesia, or for those patients who refuse surgery. Safety of use of ursodiol beyond 24 months is not established. Ursodiol capsules are indicated for the prevention of gallstone formation in obese patients experiencing rapid weight loss.

Ocaliva

Generic Name
Obeticholic

Ocaliva

Generic Name
Obeticholic
OCALIVA ® is indicated for the treatment of adult patients with primary biliary cholangitis (PBC) without cirrhosis or with compensated cirrhosis who do not have evidence of portal hypertension, either in combination with ursodeoxycholic acid (UDCA) with an inadequate response to UDCA or as monotherapy in patients unable to tolerate UDCA. This indication is approved under accelerated approval based on a reduction in alkaline phosphatase (ALP). An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. OCALIVA, a farnesoid X receptor (FXR) agonist, is indicated for the treatment of adult patients with primary biliary cholangitis (PBC) without cirrhosis or with compensated cirrhosis who do not have evidence of portal hypertension, either in combination with ursodeoxycholic acid (UDCA) with an inadequate response to UDCA or as monotherapy in patients unable to tolerate UDCA. This indication is approved under accelerated approval based on a reduction in alkaline phosphatase (ALP). An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. ( 1 )

Livdelzi

Generic Name
Seladelpar

Livdelzi

Generic Name
Seladelpar
LIVDELZI is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. This indication is approved under accelerated approval based on a reduction of alkaline phosphatase (ALP). Improvement in survival or prevention of liver decompensation events have not been demonstrated. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). LIVDELZI is a peroxisome proliferator-activated receptor (PPAR)-delta agonist indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. This indication is approved under accelerated approval based on a reduction of alkaline phosphatase (ALP). Improvement in survival or prevention of liver decompensation events have not been demonstrated. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). ( 1 ) Limitations of Use Use of LIVDELZI is not recommended in patients who have or develop decompensated cirrhosis (e.g., ascites, variceal bleeding, hepatic encephalopathy).

Iqirvo

Generic Name
Elafibranor

Iqirvo

Generic Name
Elafibranor
IQIRVO is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. This indication is approved under accelerated approval based on reduction of alkaline phosphatase (ALP). Improvement in survival or prevention of liver decompensation events have not been demonstrated. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). IQIRVO is a peroxisome proliferator-activated receptor (PPAR) agonist indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. This indication is approved under accelerated approval based on reduction of alkaline phosphatase (ALP). Improvement in survival or prevention of liver decompensation events have not been demonstrated. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). ( 1 ) Limitations of Use Use of IQIRVO is not recommended in patients who have or develop decompensated cirrhosis (e.g., ascites, variceal bleeding, hepatic encephalopathy).
Showing 1-4 of 4
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances